Suma Krishnan Sells 25,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Krystal Biotech Trading Down 5.6 %

Shares of NASDAQ:KRYS opened at $163.64 on Friday. The firm’s 50 day moving average is $181.54 and its two-hundred day moving average is $184.87. The firm has a market capitalization of $4.71 billion, a P/E ratio of 92.45 and a beta of 0.80. Krystal Biotech, Inc. has a 52 week low of $107.50 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the previous year, the business earned ($0.67) EPS. The firm’s revenue for the quarter was up 879.9% on a year-over-year basis. Analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Institutional Investors Weigh In On Krystal Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. EFG Asset Management North America Corp. grew its position in Krystal Biotech by 0.5% in the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after buying an additional 60 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of Krystal Biotech by 11.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock worth $173,000 after buying an additional 94 shares in the last quarter. Arizona State Retirement System lifted its stake in shares of Krystal Biotech by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock worth $945,000 after acquiring an additional 108 shares during the period. Fiera Capital Corp boosted its holdings in shares of Krystal Biotech by 0.8% in the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock valued at $2,976,000 after acquiring an additional 130 shares in the last quarter. Finally, KBC Group NV increased its stake in shares of Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company’s stock valued at $117,000 after acquiring an additional 132 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on KRYS. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Citigroup raised their price target on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, Stifel Nicolaus upped their price objective on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $206.67.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).